A Diagnostic Dilemma: New Enhancing Suspicious Findings on Breast MRI Following Neoadjuvant Chemotherapy
Journal of Breast Imaging · 2023
DOI: 10.1093/jbi/wbad035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Breast Imaging, 2023. Verfasst von Jennifer R LaRoy und 3 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, Department of Radiology, New York, NY, USA. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, P30 Cancer Center Support Grant.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
Evaluate the incidence and outcome of new enhancing findings on breast MRI after neoadjuvant chemotherapy (NAC).
Methods
This IRB-approved retrospective review included women with breast cancer undergoing MRI to evaluate NAC response at our institution from January 1, 1998 to March 3, 2021. Post-NAC MRIs given BI-RADS 4 or 5 with new enhancing findings were identified. Patients were excluded if they lacked pretreatment MRI or insufficient follow-up, or if the finding was a satellite of the primary tumor. Medical records and imaging studies were reviewed to identify patients and to find characteristics and outcomes.
Results
Over the study period, 2880 post-NAC breast MRIs were performed. Of 128 post-NAC MRIs given BI-RADS 4 or 5 (4.4%), 35 new suspicious findings were found on 32 MRIs, incidence rate 1.1% (32/2880). Most were characterized as nonmass enhancement (17/35, 49%), followed by mass (11/35, 31%), and then focus (7/35, 20%), with an average maximum dimension of 1.3 cm (range 0.3–7.1 cm). New findings were ipsilateral to the index cancer in 20/35 (57%) of cases. Of the 35 suspicious findings, 22 underwent image-guided biopsy (62%), 1 was surgically excised (3%), 7 underwent mastectomy (20%), 5 were stable or resolved on follow-up (8%), and none were malignant. Thirty-three were benign (94%), and two were benign high-risk lesions (atypical ductal hyperplasia, radial scar) (6%).
Conclusion
New suspicious breast MRI findings after NAC are uncommon with a low likelihood of malignancy. Further study is warranted using multi-institutional data for this low incidence finding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Memorial Sloan Kettering Cancer Center, Department of Radiology, New York, NY, USA.
- Memorial Sloan Kettering Cancer Center, Department of Surgery, New York, NY, USA.
- Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, New York, NY, USA.
ORCID-Profile: Victoria L Mango
Förderung
- NCI NIH HHS
- P30 Cancer Center Support Grant
Zitieren
APA
LaRoy, J. R., Tadros, A. B., Sevilimedu, V., & Mango, V. L. (2023). A Diagnostic Dilemma: New Enhancing Suspicious Findings on Breast MRI Following Neoadjuvant Chemotherapy. Journal of Breast Imaging. https://doi.org/10.1093/jbi/wbad035
Vancouver
LaRoy JR, Tadros AB, Sevilimedu V, Mango VL. A Diagnostic Dilemma: New Enhancing Suspicious Findings on Breast MRI Following Neoadjuvant Chemotherapy. Journal of Breast Imaging. 2023. doi:10.1093/jbi/wbad035
BibTeX
@article{LaRoy2023,
author = {LaRoy, Jennifer R and Tadros, Audree B and Sevilimedu, Varadan and Mango, Victoria L},
title = {A Diagnostic Dilemma: New Enhancing Suspicious Findings on Breast MRI Following Neoadjuvant Chemotherapy},
journal = {Journal of Breast Imaging},
year = {2023},
doi = {10.1093/jbi/wbad035}
}
EUVIMED